Screening peptide array library for the identification of cancer cell-binding peptides

Area of Science:

• Biotechnology and Biomedical Engineering
• Cancer Research and Therapeutics
• Molecular Biology and Peptide Chemistry

Background:

• Targeted delivery of chemotherapeutic agents relies on identifying cancer cell-specific ligands.
• Phage display is a common method for discovering cancer-specific peptides via biopanning.
• Synthetic peptide arrays offer a complementary approach for screening and identifying such ligands.

Purpose of the Study:

• To describe and validate a peptide array-whole cell binding assay for identifying cancer cell-specific peptides.
• To demonstrate the utility of this assay as an alternative or complementary tool to phage display.
• To identify novel peptide candidates for applications in cancer-targeted drug delivery, imaging, and diagnosis.

Main Methods:

• Synthesis of a peptide array library based on a lead dodecapeptide (p160) using solid-phase chemistry and robotic synthesis on a cellulose membrane.
• Evaluation of relative binding affinity by incubating the synthesized peptide library with fluorescently labeled cancerous and non-cancerous cells.
• Analysis of binding data to identify peptides exhibiting selective and high affinity for cancer cells.

Main Results:

• Successful synthesis and application of a peptide array library for whole-cell binding assays.
• Demonstration of the assay's capability to differentiate binding affinities between cancerous and non-cancerous cells.
• Identification of specific peptides with selective binding to cancer cells, validated through the assay.

Conclusions:

• The developed peptide array-whole cell binding assay is an effective method for discovering cancer cell-specific peptides.
• These identified peptides hold significant potential as candidates for targeted cancer therapy, diagnostic tools, and imaging agents.
• This approach provides a valuable complementary strategy to existing methods like phage display for cancer ligand discovery.